Skip to search formSkip to main contentSkip to account menu

peginesatide

Known as: Erythropoiesis-Stimulating Agent (ESA) 
A synthetic, non-recombinant, pegylated, peptidic erythropoiesis stimulating agent. Synthetic peptide-based erythropoiesis stimulating agent binds to… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

AF-37702
Erythropoiesis-stimulating Agent [EPC]Erythropoietin

Broader (1)

Peptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
2013
2013
Anemia treatment in patients with chronic kidney disease.
Anemia develops in most persons with progressive chronic kidney disease. When it becomes severe, the administration of… 
2013
2013
Anaemia: The safety and efficacy of peginesatide in patients with CKD
Recently published data from four phase 3 safety and efficacy trials show that the synthetic peptide-based, erythropoietin… 
2012
2012
A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: better results for less work.
BACKGROUND Many anaemia management algorithms recommend changes to erythropoiesis-stimulating agent (ESA) doses based on frequent… 
Review
2012
Review
2012
New anemia therapies: translating novel strategies from bench to bedside.
Recombinant human erythropoietin (epoetin) has been available for the treatment of renal anemia for more than 20 years, and… 
2012
2012
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an…
Darbepoetin alfa (DA) is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anemia (CIA… 
Review
2009
Review
2009
What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?
Randomized controlled trials (RCTs) clearly indicate a possible cardiovascular morbidity and mortality risk when deliberately… 
2008
2008
Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
Darbepoetin alfa is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anemia. This phase II… 
2008
2008
Preclinical Safety and Pharmacology of Hematide™, a Peptidic Erythropoiesis Stimulating Agent (ESA), in Rats and Monkeys
The pharmacology, toxicokinetics, and safety of HematideTM, a synthetic peptidic erythropoiesis-stimulating agent (ESA), were… 
2006
2006
Cancer-related anaemia management in the 21st century.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)